

## AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

2(Previously Presented). The method according to claim 4, wherein said compound of formula I and said selective estrogen receptor modulator are delivered in a single composition.

3(Previously Presented). The method according to claim 4, wherein said compound of formula I and said selective estrogen receptor modulator are delivered separately.

4(Currently Amended). A method of inducing contraception comprising delivering to a female of child-bearing age a composition comprising a compound of formula I in a regimen which involves delivering a pharmaceutically effective amount of one or more selective estrogen receptor modulator selected from the group consisting of EM-800, EM-652, raloxifene hydrochloride, arzoxifene, lasofoxifene, droloxifene, tamoxifen citrate, 4-hydroxytamoxifen citrate, clomiphene citrate, toremifene citrate, pipendoxifene, idoxifene, levormeloxifene, centchroman, nafoxidene, and bazedoxifene to said female, wherein formula I is:



I

wherein:

$R^1$  and  $R^2$  are joined to form  $-\text{CH}_2(\text{CH}_2)_n\text{CH}_2-$ ;

n is 3 or 4 ~~or 5~~;

R<sup>3</sup> is H;

R<sup>4</sup> is H;

R<sup>5</sup> is a five membered heterocyclic ring having 1 heteroatom selected from the group consisting of O, S, SO, and NR<sup>6</sup> and having one CN ~~or two~~ and one independent substituents selected from the group consisting of H, halogen, ~~CN~~, C<sub>1</sub> to C<sub>3</sub> alkyl, and CSR<sup>D</sup>;

R<sup>D</sup> is NH<sub>2</sub>;

R<sup>6</sup> is H or C<sub>1</sub> to C<sub>3</sub> alkyl;

Q<sup>1</sup> is S;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.


5(Previously Presented). The method according to claim 4, wherein said compound is delivered at a daily dosage of about 0.1 to about 50 mg.

6(Previously Presented). The method according to claim 4, wherein said regimen comprises delivering said composition daily for 1 to about 21 days, wherein said regimen is a cycle which is repeated monthly.

7(Previously Presented). The method according to claim 4, wherein said selective estrogen receptor modulator is delivered at a daily dosage of about 0.2 to about 100 mg.

8(Cancelled).

9(Currently Amended). The method according to Claim 4, wherein R<sup>5</sup> is the five membered ring having the structure:



U is O, S, or NR<sup>6</sup>;

X' is selected from the group consisting of halogen, CN, and CSNH<sub>2</sub>;


Y' is H.

10-13(Cancelled).

14(Previously Presented). The method according to claim 4, wherein said compound is selected from the group consisting of 4-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-thiophenecarbonitrile, 4-Methyl-5-(1,2-dihydro-2-thioxospiro[cyclohexane-1,3-[3H]-indol]-5-yl)-2-thiophenethioamide, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5'-yl)-1H-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1H-pyrrole-2-carbonitrile, 5-(2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-3-thiophenecarbonitrile, 5-(1,2-Dihydro-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-2-thiophenecarbonitrile, 5-(5-Chloro-2-thienyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-3-furancarbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl-2-thiophenecarbonitrile, 4-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-furancarbonitrile, 5-(1'',2''-Dihydro-2''-thioxospiro[cyclohexane-1,3''-[3H]indol]-5''-yl)-4-methyl-2-thiophenecarbonitrile, 5-(1'',2''-Dihydro-2''-thioxospiro[cyclohexane-1,3''-[3H]indol]-5''-yl)-2-thiophenecarbonitrile, and a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

15-43(Cancelled).

44(New). A method of inducing contraception comprising delivering to a female of child-bearing age a composition comprising a compound of formula I in a regimen which involves delivering a pharmaceutically effective amount of one or more selective estrogen receptor modulator selected from the group consisting of EM-800, EM-652, raloxifene hydrochloride, arzoxifene, lasofoxifene, droloxifene, tamoxifen citrate, 4-hydroxytamoxifen citrate, clomiphene citrate, toremifene citrate, pipendoxifene, idoxifene, levormeloxifene, centchroman, nafoxidene, and bazedoxifene to said female, wherein formula I is:



wherein:

$R^1$  and  $R^2$  are joined to form  $-\text{CH}_2(\text{CH}_2)_n\text{CH}_2-$ ;

$n$  is 3 or 4;

$R^3$  is H;

$R^4$  is H;

$R^5$  is a five membered heterocyclic ring having 1 O or S heteroatom and having one CN and one substituent selected from the group consisting of H, halogen,  $\text{C}_1$  to  $\text{C}_3$  alkyl, and  $\text{CSR}^D$ ;

$R^D$  is  $\text{NH}_2$ ;

$R^6$  is H or  $\text{C}_1$  to  $\text{C}_3$  alkyl;

$Q^1$  is S;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

45(New). The method according to claim 44, wherein said compound of formula I and said selective estrogen receptor modulator are delivered in a single composition.


46(New). The method according to claim 44, wherein said compound of formula I and said selective estrogen receptor modulator are delivered separately.

47(New). The method according to claim 44, wherein said compound is delivered at a daily dosage of about 0.1 to about 50 mg.

48(New). The method according to claim 44, wherein said regimen comprises delivering said composition daily for 1 to about 21 days, wherein said regimen is a cycle which is repeated monthly.

49(New). The method according to claim 44, wherein said selective estrogen receptor modulator is delivered at a daily dosage of about 0.2 to about 100 mg.

50(New). A method of inducing contraception comprising delivering to a female of child-bearing age a composition comprising a compound of formula I in a regimen which involves delivering a pharmaceutically effective amount of one or more selective estrogen receptor modulator selected from the group consisting of EM-800, EM-652, raloxifene hydrochloride, arzoxifene, lasofoxifene, droloxifene, tamoxifen citrate, 4-hydroxytamoxifen citrate, clomiphene citrate, toremifene citrate, pibendoxifene, idoxifene, levormeloxifene, centchroman, nafoxidene, and bazedoxifene to said female, wherein formula I is:



I

wherein:

$R^1$  and  $R^2$  are joined to form  $-\text{CH}_2(\text{CH}_2)_n\text{CH}_2-$ ;

$n$  is 3 or 4;

$R^3$  is H;

$R^4$  is H;

$R^5$  is a five membered heterocyclic ring having 1  $NR^6$  heteroatom and having one CN and one substituent selected from the group consisting of H, halogen,  $C_1$  to  $C_3$  alkyl, and  $CSR^D$ ;

$R^D$  is  $NH_2$ ;

$R^6$  is H or  $C_1$  to  $C_3$  alkyl;

$Q^1$  is S;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

51(New). The method according to claim 50, wherein said compound of formula I and said selective estrogen receptor modulator are delivered in a single composition.

52(New). The method according to claim 50, wherein said compound of formula I and said selective estrogen receptor modulator are delivered separately.

53(New). The method according to claim 50, wherein said compound is delivered at a daily dosage of about 0.1 to about 50 mg.

54(New). The method according to claim 50, wherein said regimen comprises delivering said composition daily for 1 to about 21 days, wherein said regimen is a cycle which is repeated monthly.

55(New). The method according to claim 50, wherein said selective estrogen receptor modulator is delivered at a daily dosage of about 0.2 to about 100 mg.